Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q3 2021 · 10-Q
Revenue$4.06M$4.06M+38.0% vs Q3 2020 Net Income-$16.54M-$16.54MN/M vs Q3 2020 EPS Diluted-$0.24-$0.24N/M vs Q3 2020 Operating Income-$19,012,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$14,834,000N/M Margins · derivedOperating margin-468.6%−26.3 pt vs Q3 2020
Net margin-407.6%+78.4 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 2, 2021 · 33 d after period end